Immunotherapy for deficient mismatch repair (dMMR) pancreatic ductal adenocarcinoma

Matthew I Ebia; Megan P Hitchins; Andrew E Hendifar

doi:10.21037/jgo-23-12

Immunotherapy for deficient mismatch repair (dMMR) pancreatic ductal adenocarcinoma

J Gastrointest Oncol. 2023 Apr 29;14(2):1175-1177. doi: 10.21037/jgo-23-12. Epub 2023 Mar 7.

Authors

Matthew I Ebia¹, Megan P Hitchins², Andrew E Hendifar^{1

3}

Affiliations

¹ Division of Hematology and Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
² Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
³ Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA.

No abstract available

Keywords: DNA deficient mismatch repair (DNA dMMR); Lynch syndrome; Pancreatic ductal adenocarcinoma (PDAC); immunotherapy; microsatellite instability (MSI).

Publication types

Editorial
Comment